Corcept Therapeutics
American pharmaceutical company
CORT Nasdaq
ISIN US2183521028 SEC CIK 1088856
Follow Corcept Therapeutics
Weekly email: filings, results
Revenue, last quarter
$340.5M
+64% vs same quarter last year
Net income
$126.8M
+544.6% vs same quarter last year
EPS, diluted
$1.01
+531.3% vs same quarter last year
Operating cash flow
$142.9M
+162.3% vs same quarter last year
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | $761.4M | $99.7M |
| FY24 | $675M | $141.2M |
| FY23 | $482.4M | $106.1M |
| FY22 | $401.9M | $101.4M |
| FY21 | $366M | $112.5M |
| FY20 | $353.9M | $106M |
| FY19 | $306.5M | $94.2M |
| FY18 | $251.2M | $75.4M |
| FY17 | $159.2M | $129.1M |
| FY16 | $81.3M | $8.1M |
| FY15 | $50.3M | −$6.4M |
| FY14 | $26.6M | −$31.4M |
| FY13 | $10.4M | −$46M |
| FY12 | $3.3M | −$38M |
| FY11 | - | −$32.4M |
- Gross margin
- Operating margin
- Net margin
Show the numbers
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| FY25 | 98.3% | 5.9% | 13.1% |
| FY24 | 98.4% | 20.3% | 20.9% |
| FY23 | 98.7% | 22.2% | 22% |
| FY22 | 98.7% | 28% | 25.2% |
| FY21 | 98.6% | 34% | 30.7% |
| FY20 | 98.4% | 36.2% | 30% |
| FY19 | 98.2% | 36.4% | 30.7% |
| FY18 | 97.9% | 35.6% | 30% |
| FY17 | 97.8% | 33.2% | 81.1% |
| FY16 | 97.5% | 12.5% | 10% |
| FY15 | 97.3% | −6.8% | −12.7% |
| FY14 | 96.7% | −104% | −118.2% |
| FY13 | 98.6% | −400.7% | −444.3% |
| FY12 | 97.2% | −1096.8% | −1150.5% |
| FY11 | - | - | - |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | $141.8M |
| FY24 | $196.1M |
| FY23 | $126.5M |
| FY22 | $119.9M |
| FY21 | $167.4M |
| FY20 | $150.7M |
| FY19 | $135M |
| FY18 | $115.4M |
| FY17 | $60.5M |
| FY16 | $18.2M |
| FY15 | $3.1M |
| FY14 | −$27.6M |
| FY13 | −$37.2M |
| FY12 | −$36.2M |
| FY11 | −$27.4M |
Show the numbers
| Year | Buybacks |
|---|---|
| FY25 | $172.9M |
| FY24 | $15.7M |
| FY23 | $0 |
| FY22 | $0 |
| FY21 | - |
| FY20 | $9.9M |
| FY19 | $31M |
| FY18 | $23.7M |
| FY17 | $0 |
| FY16 | $0 |
| FY15 | - |
| FY14 | - |
| FY13 | - |
| FY12 | - |
| FY11 | - |
- Corcept Therapeutics
- Healthcare median
Show the numbers
| Year | Corcept Therapeutics | Healthcare median |
|---|---|---|
| FY25 | 13.1% | −30.6% |
| FY24 | 20.9% | −47% |
| FY23 | 22% | −58% |
| FY22 | 25.2% | −80.4% |
| FY21 | 30.7% | −71.8% |
| FY20 | 30% | −62.2% |
| FY19 | 30.7% | −46.2% |
| FY18 | 30% | −49.6% |
| FY17 | 81.1% | −45.9% |
| FY16 | 10% | −36% |
| FY15 | −12.7% | −37.8% |
| FY14 | −118.2% | −35.5% |
| FY13 | −444.3% | −37.1% |
| FY12 | −1150.5% | −29.1% |
| FY11 | - | −27.9% |